{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:07:22Z","timestamp":1763017642596},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,5,21]],"date-time":"2016-05-21T00:00:00Z","timestamp":1463788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00277-016-2697-8","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T02:37:07Z","timestamp":1464057427000},"page":"537-548","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Managing patients with myelofibrosis and low platelet counts"],"prefix":"10.1007","volume":"96","author":[{"given":"Haifa Kathrin","family":"Al-Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,21]]},"reference":[{"key":"2697_CR1","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/ajh.23703","volume":"89","author":"A Tefferi","year":"2014","unstructured":"Tefferi A (2014) Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89:915\u2013925. doi: 10.1002\/ajh.23703","journal-title":"Am J Hematol"},{"key":"2697_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, et al. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937\u2013951. doi: 10.1182\/blood-2009-03-209262","journal-title":"Blood"},{"key":"2697_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev.med.60.041707.160528","volume":"60","author":"OI Abdel-Wahab","year":"2009","unstructured":"Abdel-Wahab OI, Levine RL (2009) Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med 60:233\u2013245. doi: 10.1146\/annurev.med.60.041707.160528","journal-title":"Annu Rev Med"},{"key":"2697_CR4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054\u20131061. doi: 10.1016\/S0140-6736(05)71142-9","journal-title":"Lancet"},{"key":"2697_CR5","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic JP, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144\u20131148. doi: 10.1038\/nature03546","journal-title":"Nature"},{"key":"2697_CR6","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/nejmoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779\u20131790. doi: 10.1056\/nejmoa051113","journal-title":"N Engl J Med"},{"key":"2697_CR7","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, et al. (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270. doi: 10.1371\/journal.pmed.0030270","journal-title":"PLoS Med"},{"key":"2697_CR8","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/nejmoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, et al. (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379\u20132390. doi: 10.1056\/nejmoa1311347","journal-title":"N Engl J Med"},{"key":"2697_CR9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/nejmoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, et al. (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391\u20132405. doi: 10.1056\/nejmoa1312542","journal-title":"N Engl J Med"},{"key":"2697_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/cncr.22365","volume":"109","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JA, Tefferi A (2007) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 109:68\u201376. doi: 10.1002\/cncr.22365","journal-title":"Cancer"},{"key":"2697_CR11","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/jco.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL, et al. (2012) Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 30:4098\u20134103. doi: 10.1200\/jco.2012.42.3863","journal-title":"J Clin Oncol"},{"key":"2697_CR12","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1182\/blood-2013-09-527903","volume":"123","author":"HL Geyer","year":"2014","unstructured":"Geyer HL, Scherber RM, Dueck AC, et al. (2014) Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood 123:3803\u20133810. doi: 10.1182\/blood-2013-09-527903","journal-title":"Blood"},{"key":"2697_CR13","doi-asserted-by":"publisher","unstructured":"Gowin K, Emanuel R, Geyer H, Mesa RA (2013) The new landscape of therapy for myelofibrosis. Curr Hematol Malig Rep 8:325\u2013332. doi: 10.1007\/s11899-013-0178-x","DOI":"10.1007\/s11899-013-0178-x"},{"key":"2697_CR14","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, et al. (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895\u20132901. doi: 10.1182\/blood-2008-07-170449","journal-title":"Blood"},{"key":"2697_CR15","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, et al. (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115:1703\u20131708. doi: 10.1182\/blood-2009-09-245837","journal-title":"Blood"},{"key":"2697_CR16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/jco.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, et al. (2011) DIPSS Plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29:392\u2013397. doi: 10.1200\/jco.2010.32.2446","journal-title":"J Clin Oncol"},{"key":"2697_CR17","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.leukres.2013.08.008","volume":"37","author":"P Guglielmelli","year":"2013","unstructured":"Guglielmelli P, Vannucchi AM (2013) Struggling with myelofibrosis-associated anemia. Leuk Res 37:1429\u20131431. doi: 10.1016\/j.leukres.2013.08.008","journal-title":"Leuk Res"},{"key":"2697_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","volume":"87","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Lasho TL, Jimma T, et al. (2012) One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc 87:25\u201333. doi: 10.1016\/j.mayocp.2011.11.001","journal-title":"Mayo Clin Proc"},{"key":"2697_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1365-2141.2004.05229.x","volume":"127","author":"F Cervantes","year":"2004","unstructured":"Cervantes F, Alvarez-Larr\u00e1n A, Hern\u00e1ndez-Boluda JC, Sureda A, Torrebadell M, Montserrat E (2004) Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 127:399\u2013403. doi: 10.1111\/j.1365-2141.2004.05229.x","journal-title":"Br J Haematol"},{"key":"2697_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1600-0609.2009.01266.x","volume":"83","author":"J Huang","year":"2009","unstructured":"Huang J, Tefferi A (2009) Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 83:154\u2013155. doi: 10.1111\/j.1600-0609.2009.01266.x","journal-title":"Eur J Haematol"},{"key":"2697_CR21","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/j.1365-2141.2005.05524.x","volume":"129","author":"F Cervantes","year":"2005","unstructured":"Cervantes F, Alvarez-Larr\u00e1n A, Domingo A, Arellano-Rodrigo E, Montserrat E (2005) Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 129:771\u2013775. doi: 10.1111\/j.1365-2141.2005.05524.x","journal-title":"Br J Haematol"},{"key":"2697_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1532\/ijh97.06135","volume":"85","author":"K Shimoda","year":"2007","unstructured":"Shimoda K, Shide K, Kamezaki K, et al. (2007) The effect of anabolic steroids on anemia in myelofibrosis with myeloid metaplasia: retrospective analysis of 39 patients in Japan. Int J Hematol 85:338\u2013343. doi: 10.1532\/ijh97.06135","journal-title":"Int J Hematol"},{"key":"2697_CR23","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","volume":"101","author":"RA Mesa","year":"2003","unstructured":"Mesa RA, Steensma DP, Pardanani A, et al. (2003) A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 101:2534\u20132541. doi: 10.1182\/blood-2002-09-2928","journal-title":"Blood"},{"key":"2697_CR24","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","volume":"108","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Cortes J, Verstovsek S, et al. (2006) Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 108:1158\u20131164. doi: 10.1182\/blood-2006-02-004572","journal-title":"Blood"},{"key":"2697_CR25","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1038\/sj.leu.2404711","volume":"21","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA (2007) Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 21:1827\u20131828. doi: 10.1038\/sj.leu.2404711","journal-title":"Leukemia"},{"key":"2697_CR26","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1200\/jco.2009.22.6548","volume":"27","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S (2009) Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 27:4760\u20134766. doi: 10.1200\/jco.2009.22.6548","journal-title":"J Clin Oncol"},{"key":"2697_CR27","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.leukres.2013.07.007","volume":"37","author":"N Daver","year":"2013","unstructured":"Daver N, Shastri A, Kadia T, Quint\u00e1s-Cardama A, Jabbour E, Konopleva M, O\u2019Brien S, Pierce S (2013) Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res 37:1440\u20131444. doi: 10.1016\/j.leukres.2013.07.007","journal-title":"Leuk Res"},{"key":"2697_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/ajh.22233","volume":"87","author":"KH Begna","year":"2012","unstructured":"Begna KH, Pardanani A, Mesa R, Litzow MR, Hogan WJ, Hanson CA, Tefferi A (2012) Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol 87:66\u201368. doi: 10.1002\/ajh.22233","journal-title":"Am J Hematol"},{"key":"2697_CR29","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.leukres.2014.06.015","volume":"38","author":"N Daver","year":"2014","unstructured":"Daver N, Shastri A, Kadia T, et al. (2014) Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res 38:1126\u20131129. doi: 10.1016\/j.leukres.2014.06.015","journal-title":"Leuk Res"},{"key":"2697_CR30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/leu.2010.234","volume":"25","author":"D Caramazza","year":"2011","unstructured":"Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL, Hanson C, Pardanani A, Tefferi A (2011) Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 25:82\u201388. doi: 10.1038\/leu.2010.234","journal-title":"Leukemia"},{"key":"2697_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1179\/2295333714Y.0000000097","volume":"70","author":"T Devos","year":"2015","unstructured":"Devos T, Zach\u00e9e P, Bron D, et al. (2015) Myelofibrosis patients in Belgium: disease characteristics. Acta Clin Belg 70:105\u2013111. doi: 10.1179\/2295333714Y.0000000097","journal-title":"Acta Clin Belg"},{"key":"2697_CR32","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1200\/jco.2009.22.8833","volume":"27","author":"CS Tam","year":"2009","unstructured":"Tam CS, Kantarjian H, Cortes J, Lynn A, Pierce S, Zhou L, Keating MJ, Thomas DA, Verstovsek S (2009) Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis. J Clin Oncol 27:5587\u20135593. doi: 10.1200\/jco.2009.22.8833","journal-title":"J Clin Oncol"},{"key":"2697_CR33","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/leu.2011.374","volume":"26","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Pardanani A, Gangat N, et al. (2012) Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia 26:1439\u20131441. doi: 10.1038\/leu.2011.374","journal-title":"Leukemia"},{"key":"2697_CR34","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.3324\/haematol.2013.101733","volume":"99","author":"JC Hern\u00e1ndez-Boluda","year":"2014","unstructured":"Hern\u00e1ndez-Boluda JC, Pereira A, G\u00f3mez M, et al. (2014) The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. Haematologica 99:e55\u2013e57. doi: 10.3324\/haematol.2013.101733","journal-title":"Haematologica"},{"key":"2697_CR35","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/nejmoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799\u2013807. doi: 10.1056\/nejmoa1110557","journal-title":"N Engl J Med"},{"key":"2697_CR36","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1586\/17474086.2013.827413","volume":"6","author":"C Harrison","year":"2013","unstructured":"Harrison C, Mesa R, Ross D, Mead A, Keohane C, Gotlib J, Verstovsek S (2013) Practical management of patients with myelofibrosis receiving ruxolitinib. Expert Rev Hematol 6:511\u2013523. doi: 10.1586\/17474086.2013.827413","journal-title":"Expert Rev Hematol"},{"key":"2697_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/IJGM.S51800; 10.2147\/ijgm.s51800","volume":"7","author":"TI Mughal","year":"2014","unstructured":"Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S (2014) Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med 7:89\u2013101. doi: 10.2147\/IJGM.S51800; 10.2147\/ijgm.s51800","journal-title":"Int J Gen Med"},{"key":"2697_CR38","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1053\/j.seminhematol.2008.12.001","volume":"46","author":"AM Boruchov","year":"2009","unstructured":"Boruchov AM (2009) Thrombocytopenia in myelodysplastic syndromes and myelofibrosis. Semin Hematol 46:S37\u2013S43. doi: 10.1053\/j.seminhematol.2008.12.001","journal-title":"Semin Hematol"},{"key":"2697_CR39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/ijlh.12214","volume":"36","author":"KJ Smock","year":"2014","unstructured":"Smock KJ, Perkins SL (2014) Thrombocytopenia: an update. Int J Lab Hematol 36:269\u2013278. doi: 10.1111\/ijlh.12214","journal-title":"Int J Lab Hematol"},{"key":"2697_CR40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-0609.1985.tb02252.x","volume":"34","author":"H Hasselbalch","year":"1985","unstructured":"Hasselbalch H, Nielsen H, Berild D, Kappelgaard E (1985) Circulating immune complexes in myelofibrosis. Scand J Haematol 34:177\u2013180","journal-title":"Scand J Haematol"},{"key":"2697_CR41","doi-asserted-by":"crossref","unstructured":"Tefferi A, Guglielmelli P, Larson DR, et al. (2014) Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis. Blood 124:2507\u20132513","DOI":"10.1182\/blood-2014-05-579136"},{"key":"2697_CR42","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1600-0609.2009.01373.x","volume":"84","author":"MM Patnaik","year":"2010","unstructured":"Patnaik MM, Caramazza D, Gangat N, Hanson CA, Pardanani A, Tefferi A (2010) Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol 84:105\u2013108. doi: 10.1111\/j.1600-0609.2009.01373.x","journal-title":"Eur J Haematol"},{"key":"2697_CR43","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1002\/cncr.23505","volume":"112","author":"J Huang","year":"2008","unstructured":"Huang J, Li CY, Mesa RA, Wu W, Hanson CA, Pardanani A, Tefferi A (2008) Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 112:2726\u20132732. doi: 10.1002\/cncr.23505","journal-title":"Cancer"},{"key":"2697_CR44","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s12185-015-1871-4","volume":"102","author":"EM Kander","year":"2015","unstructured":"Kander EM, Raza S, Zhou Z, Gao J, Zakarija A, McMahon BJ, Stein BL (2015) Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. Int J Hematol 102:587\u2013593. doi: 10.1007\/s12185-015-1871-4","journal-title":"Int J Hematol"},{"key":"2697_CR45","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/leu.2011.258","volume":"26","author":"G Finazzi","year":"2011","unstructured":"Finazzi G, Carobbio A, Thiele J, et al. (2011) Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 26:716\u2013719. doi: 10.1038\/leu.2011.258","journal-title":"Leukemia"},{"key":"2697_CR46","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/bmj.2.5914.324","volume":"2","author":"P Barkhan","year":"1974","unstructured":"Barkhan P (1974) Blood and neoplastic diseases. Thrombocytopenia. Br Med J 2:324\u2013325","journal-title":"Br Med J"},{"key":"2697_CR47","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1538-7836.2009.03360.x","volume":"7","author":"RH Aster","year":"2009","unstructured":"Aster RH, Curtis BR, McFarland JG, Bougie DW (2009) Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost 7:911\u2013918. doi: 10.1111\/j.1538-7836.2009.03360.x","journal-title":"J Thromb Haemost"},{"key":"2697_CR48","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, et al. (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29:761\u2013770. doi: 10.1200\/JCO.2010.31.8436","journal-title":"J Clin Oncol"},{"key":"2697_CR49","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00277-010-1019-9","volume":"89","author":"A Martinez-Trillos","year":"2010","unstructured":"Martinez-Trillos A, Gaya A, Maffioli M, Arellano-Rodrigo E, Calvo X, Diaz-Beya M, Cervantes F (2010) Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 89:1233\u20131237. doi: 10.1007\/s00277-010-1019-9","journal-title":"Ann Hematol"},{"key":"2697_CR50","unstructured":"European Medicines Agency (2014) Siklos (hydroxycarbamide) [summary of product characteristics]. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000689\/WC500050503.pdf . Accessed 1 March 2016"},{"key":"2697_CR51","unstructured":"Bristol-Myers Squibb (2015) Hydrea (hydroxyurea) [package insert]. http:\/\/packageinserts.bms.com\/pi\/pi_hydrea.pdf . Accessed 1 March 2016"},{"key":"2697_CR52","unstructured":"European Medicines Agency (2015) Jakavi (ruxolitinib) [summary of product characteristics]. http:\/\/ec.europa.eu\/health\/documents\/community-register\/2012\/20120823123254\/anx_123254_en.pdf . Accessed 1 March 2016"},{"key":"2697_CR53","unstructured":"Incyte Corporation\u00a0(2014) Jakafi (ruxolitinib) [package insert]. https:\/\/www.jakafi.com\/pdf\/prescribing-information.pdf . Accessed 1 March 2016"},{"key":"2697_CR54","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/nejmoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, et al. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787\u2013798. doi: 10.1056\/nejmoa1110556","journal-title":"N Engl J Med"},{"key":"2697_CR55","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/nejmoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, et al. (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117\u20131127. doi: 10.1056\/nejmoa1002028","journal-title":"N Engl J Med"},{"key":"2697_CR56","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3324\/haematol.2014.115840","volume":"100","author":"S Verstovsek","year":"2015","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. (2015) Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica 100:479\u2013488. doi: 10.3324\/haematol.2014.115840","journal-title":"Haematologica"},{"key":"2697_CR57","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian JJ, et al. (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122:4047\u20134053. doi: 10.1182\/blood-2013-02-485888","journal-title":"Blood"},{"key":"2697_CR58","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","volume":"100","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. (2015) A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 100:1139\u20131145","journal-title":"Haematologica"},{"key":"2697_CR59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.12703\/p6-45","volume":"6","author":"M Izak","year":"2014","unstructured":"Izak M, Bussel JB (2014) Management of thrombocytopenia. F1000Prime Rep 6:45. doi: 10.12703\/p6-45","journal-title":"F1000Prime Rep"},{"key":"2697_CR60","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s00277-015-2435-7","volume":"94","author":"F Cervantes","year":"2015","unstructured":"Cervantes F, Isola IM, Alvarez-Larran A, Hernandez-Boluda JC, Correa JG, Pereira A (2015) Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. Ann Hematol 94:1791\u20131796. doi: 10.1007\/s00277-015-2435-7","journal-title":"Ann Hematol"},{"key":"2697_CR61","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2141.2004.05301.x","volume":"128","author":"F Cervantes","year":"2005","unstructured":"Cervantes F (2005) Modern management of myelofibrosis. Br J Haematol 128:583\u2013592","journal-title":"Br J Haematol"},{"key":"2697_CR62","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.794269","author":"FP Santos","year":"2013","unstructured":"Santos FP, Tam CS, Kantarjian H, Cortes J, Thomas D, Pollock R, Verstovsek S (2013) Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma. doi: 10.3109\/10428194.2013.794269","journal-title":"Leuk Lymphoma"},{"key":"2697_CR63","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","volume":"95","author":"A Tefferi","year":"2000","unstructured":"Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN (2000) Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 95:2226\u20132233","journal-title":"Blood"},{"key":"2697_CR64","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1038\/bcj.2011.36","volume":"1","author":"F Cervantes","year":"2011","unstructured":"Cervantes F (2011) How I treat splenomegaly in myelofibrosis. Blood Cancer J 1:e37. doi: 10.1038\/bcj.2011.36","journal-title":"Blood Cancer J"},{"key":"2697_CR65","first-page":"233","volume":"160","author":"MA el-Khishen","year":"1985","unstructured":"el-Khishen MA, Henderson JM, Millikan WJ Jr, Kutner MH, Warren WD (1985) Splenectomy is contraindicated for thrombocytopenia secondary to portal hypertension. Surg Gynecol Obstet 160:233\u2013238","journal-title":"Surg Gynecol Obstet"},{"key":"2697_CR66","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1756-8722-2-36","volume":"2","author":"V Kotla","year":"2009","unstructured":"Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A (2009) Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2:36. doi: 10.1186\/1756-8722-2-36","journal-title":"J Hematol Oncol"},{"key":"2697_CR67","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","volume":"24","author":"H Quach","year":"2010","unstructured":"Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM (2010) Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24:22\u201332. doi: 10.1038\/leu.2009.236","journal-title":"Leukemia"},{"key":"2697_CR68","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3109\/10428194.2012.728597","volume":"54","author":"YX Zhu","year":"2013","unstructured":"Zhu YX, Kortuem KM, Stewart AK (2013) Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma 54:683\u2013687. doi: 10.3109\/10428194.2012.728597","journal-title":"Leuk Lymphoma"},{"key":"2697_CR69","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/jco.2004.08.160","volume":"22","author":"M Marchetti","year":"2004","unstructured":"Marchetti M, Barosi G, Balestri F, et al. (2004) Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 22:424\u2013431. doi: 10.1200\/jco.2004.08.160","journal-title":"J Clin Oncol"},{"key":"2697_CR70","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1200\/jco.2008.21.7356","volume":"27","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Verstovsek S, Barosi G, et al. (2009) Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 27:4563\u20134569. doi: 10.1200\/jco.2008.21.7356","journal-title":"J Clin Oncol"},{"key":"2697_CR71","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ajh.21598","volume":"85","author":"RA Mesa","year":"2010","unstructured":"Mesa RA, Pardanani AD, Hussein K, Wu W, Schwager S, Litzow MR, Hogan WJ, Tefferi A (2010) Phase1\/-2 study of pomalidomide in myelofibrosis. Am J Hematol 85:129\u2013130. doi: 10.1002\/ajh.21598","journal-title":"Am J Hematol"},{"key":"2697_CR72","first-page":"394","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Passamonti F, Barbui T, et al. (2013) Phase 3 study of pomalidomide in myeloproliferative neoplasm (MPN)-associated myelofibrosis with RBC-transfusion-dependence. ASH Annu Meet Abstr 122:394","journal-title":"ASH Annu Meet Abstr"},{"key":"2697_CR73","unstructured":"ClinicalTrials.gov. (2010) Phase-3 double-blind, placebo-controlled study of pomalidomide in persons with myeloproliferative-neoplasm-associated myelofibrosis and RBC-transfusion-dependence myelofibrosis and RBC-transfusion-dependence (RESUME). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01178281 . Accessed 5 January 2016"},{"key":"2697_CR74","first-page":"2822","volume":"122","author":"RF Schlenk","year":"2013","unstructured":"Schlenk RF, Stegelmann F, Reiter A, et al. (2013) Pomalidomide in MPN\u2014associated myelofibrosis with cytopenia: results of the Mpnsg 01-09 study. ASH Annu Meet Abstr 122:2822","journal-title":"ASH Annu Meet Abstr"},{"key":"2697_CR75","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/modpathol.2015.93","volume":"28","author":"M Pizzi","year":"2015","unstructured":"Pizzi M, Silver RT, Barel A, Orazi A (2015) Recombinant interferon-\u03b1 in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod Pathol 28:1315\u20131323. doi: 10.1038\/modpathol.2015.93","journal-title":"Mod Pathol"},{"key":"2697_CR76","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/bjh.12459","volume":"162","author":"JC Ianotto","year":"2013","unstructured":"Ianotto JC, Boyer-Perrard F, Gyan E, et al. (2013) Efficacy and safety of pegylated-interferon \u03b1-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol 162:783\u2013791. doi: 10.1111\/bjh.12459","journal-title":"Br J Haematol"},{"key":"2697_CR77","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","volume":"16","author":"KK Ballen","year":"2010","unstructured":"Ballen KK, Shrestha S, Sobocinski KA, et al. (2010) Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 16:358\u2013367. doi: 10.1016\/j.bbmt.2009.10.025","journal-title":"Biol Blood Marrow Transplant"},{"key":"2697_CR78","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3324\/haematol.2011.061168","volume":"97","author":"M Ditschkowski","year":"2012","unstructured":"Ditschkowski M, Elmaagacli AH, Trenschel R, Gromke T, Steckel NK, Koldehoff M, Beelen DW (2012) DIPSS scores, pre-transplant therapy and chronic GVHD determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis. Haematologica 97:1574\u20131581. doi: 10.3324\/haematol.2011.061168","journal-title":"Haematologica"},{"key":"2697_CR79","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","volume":"114","author":"N Kr\u00f6ger","year":"2009","unstructured":"Kr\u00f6ger N, Holler E, Kobbe G, et al. (2009) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 114:5264\u20135270. doi: 10.1182\/blood-2009-07-234880","journal-title":"Blood"},{"key":"2697_CR80","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1756-8722-6-81","volume":"6","author":"M Talpaz","year":"2013","unstructured":"Talpaz M, Paquette R, Afrin L, et al. (2013) Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol 6:81. doi: 10.1186\/1756-8722-6-81","journal-title":"J Hematol Oncol"},{"key":"2697_CR81","first-page":"177","volume":"120","author":"CN Harrison","year":"2012","unstructured":"Harrison CN, Gisslinger H, Miller CB, et al. (2012) EXPAND: a phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50 \u00d7 109\/L and 99 \u00d7 109\/L. ASH Annu Meet Abstr 120:177","journal-title":"ASH Annu Meet Abstr"},{"key":"2697_CR82","first-page":"1841","volume":"124","author":"P Boekhorst te","year":"2014","unstructured":"te Boekhorst P, Harrison C, Gisslinger H, Niederwieser D, Stalbovskaya V, Atienza E, Gopalakrishna P, Vannucchi A (2014) A phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis (MF) and baseline platelet counts from 50 \u00d7 109\/L to 99 \u00d7 109\/L (the EXPAND study). ASH Annu Meet Abstr 124:1841","journal-title":"ASH Annu Meet Abstr"},{"key":"2697_CR83","first-page":"0364","volume":"97","author":"CN Harrison","year":"2012","unstructured":"Harrison CN, Kiladjian JJ, Passamonti F, et al. (2012) A phase 1b dose-finding study of ruxolitinib plus panobinostat in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. EHA Annu Meet Abstr 97:0364","journal-title":"EHA Annu Meet Abstr"},{"key":"2697_CR84","first-page":"2817","volume":"126","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Gisslinger H, Harrison CN, et al. (2015) EXPAND: a phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis (MF) and low platelet counts (50 \u00d7 109\/L to 99 \u00d7 109\/L) at baseline. ASH Annu Meet Abstr 126:2817","journal-title":"ASH Annu Meet Abstr"},{"key":"2697_CR85","first-page":"3197","volume":"124","author":"B Martino","year":"2014","unstructured":"Martino B, Le Coutre P, Griesshammer M, et al. (2014) Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm, expanded-access study in patients with myelofibrosis (MF): an 1144-patient update. ASH Annu Meet Abstr 124:3197","journal-title":"ASH Annu Meet Abstr"},{"key":"2697_CR86","first-page":"P675","volume":"100","author":"P Giraldo","year":"2015","unstructured":"Giraldo P, Palandri F, Palumbo GA, et al. (2015) Safety and efficacy of ruxolitinib (RUX) in patients with intermediate-1\u2013risk myelofibrosis (MF) from an open-label, multicenter, single-arm expanded-access study. EHA Annu Meet Abstr 100:P675","journal-title":"EHA Annu Meet Abstr"},{"key":"2697_CR87","first-page":"1859","volume":"124","author":"M Griesshammer","year":"2014","unstructured":"Griesshammer M, Vannucchi A, le Coutre P, et al. (2014) Safety and efficacy of ruxolitinib in patients with low platelets enrolled in a phase 3b expanded-access study in myelofibrosis (MF). ASH Annu Meet Abstr 124:1859","journal-title":"ASH Annu Meet Abstr"},{"key":"2697_CR88","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","volume":"98","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. (2013) Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 98:1865\u20131871. doi: 10.3324\/haematol.2013.092155","journal-title":"Haematologica"},{"key":"2697_CR89","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/ott.S53348","volume":"7","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Gotlib J, Gupta V, et al. (2013) Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther 7:13\u201321. doi: 10.2147\/ott.S53348","journal-title":"Onco Targets Ther"},{"key":"2697_CR90","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1756-8722-6-79","volume":"6","author":"RA Mesa","year":"2013","unstructured":"Mesa RA, Cortes J (2013) Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol 6:79. doi: 10.1186\/1756-8722-6-79","journal-title":"J Hematol Oncol"},{"key":"2697_CR91","first-page":"1586","volume":"122","author":"A Tabarroki","year":"2013","unstructured":"Tabarroki A, Lindner D, Visconte V, et al. (2013) Modified dose escalation of ruxolitinib: a feasible therapeutic approach in the management of myelofibrosis. ASH Annu Meet Abstr 122:1586","journal-title":"ASH Annu Meet Abstr"},{"key":"2697_CR92","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00277-014-2241-7","volume":"94","author":"C Armstrong","year":"2015","unstructured":"Armstrong C, Maung SW, Neary P, McHugh J, Enright H (2015) Safety and efficacy of ruxolitinib in a profoundly thrombocytopenic patient with myelofibrosis. Ann Hematol 94:711\u2013712. doi: 10.1007\/s00277-014-2241-7","journal-title":"Ann Hematol"},{"key":"2697_CR93","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1200\/JCO.2013.51.0057","volume":"34","author":"MR Grunwald","year":"2016","unstructured":"Grunwald MR, Spivak JL (2016) Ruxolitinib enhances platelet production in patients with thrombocytopenic myelofibrosis. J Clin Oncol 34:e38\u2013e40","journal-title":"J Clin Oncol"},{"key":"2697_CR94","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3109\/10428194.2014.924121","volume":"56","author":"M Andrei","year":"2015","unstructured":"Andrei M, Sindhu H, Wang JC (2015) Two cases of myelofibrosis with severe thrombocytopenia and symptomatology successfully treated with combination of pomalidomide and ruxolitinib. Leuk Lymphoma 56:524\u2013526. doi: 10.3109\/10428194.2014.924121","journal-title":"Leuk Lymphoma"},{"key":"2697_CR95","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1021\/jm201454n","volume":"55","author":"AD William","year":"2012","unstructured":"William AD, Lee AC, Poulsen A, et al. (2012) Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18. 3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of Janus kinase 2\/fms-like tyrosine kinase-3 (JAK2\/FLT3) for the treatment of rheumatoid arthritis. J Med Chem 55:2623\u20132640. doi: 10.1021\/jm201454n","journal-title":"J Med Chem"},{"key":"2697_CR96","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/leu.2011.148","volume":"25","author":"S Hart","year":"2011","unstructured":"Hart S, Goh KC, Novotny-Diermayr V, et al. (2011) SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 25:1751\u20131759. doi: 10.1038\/leu.2011.148","journal-title":"Leukemia"},{"key":"2697_CR97","first-page":"1874","volume":"124","author":"J Singer","year":"2014","unstructured":"Singer J, Al-Fayoumi S, Ma H, Komrokji RS, Mesa R, Verstovsek S (2014) Comprehensive kinase profile of pacritinib, a non-myelosuppressive JAK2 kinase inhibitor in phase 3 development in primary and post ET\/PV myelofibrosis. ASH Annu Meet Abstr 124:1874","journal-title":"ASH Annu Meet Abstr"},{"key":"2697_CR98","first-page":"LBA7006","volume":"33","author":"RA Mesa","year":"2015","unstructured":"Mesa RA, Egyed M, Szoke A, et al. (2015) Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF). ASCO Annu Meet Abstr 33:LBA7006","journal-title":"ASCO Annu Meet Abstr"},{"key":"2697_CR99","first-page":"LB2072","volume":"100","author":"R Mesa","year":"2015","unstructured":"Mesa R, Vannucchi A, Mead A, Wang L, Yang Y, Harrison C (2015) Patient-reported outcomes (PROs) in PERSIST-1: a randomized, multi-country phase III trial of the JAK2 inhibitor pacritinib (PAC) vs. best available therapy (BAT) in myelofibrosis. EHA Annu Meet Abstr 100:LB2072","journal-title":"EHA Annu Meet Abstr"},{"key":"2697_CR100","first-page":"3905","volume":"114","author":"S Verstovsek","year":"2009","unstructured":"Verstovsek S, Odenike O, Scott B, et al. (2009) Phase I dose-escalation trial of SB1518, a novel JAK2\/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia\/polycythemia vera myelofibrosis. ASH Annu Meet Abstr 114:3905","journal-title":"ASH Annu Meet Abstr"},{"key":"2697_CR101","first-page":"1444","volume":"95","author":"JF Seymour","year":"2010","unstructured":"Seymour JF, Goh A, Meadows L, Ethirajulu A, Wood A, Zhu A, Roberts W (2010) First report of the phase I study of the novel oral JAK2 inhibitor SB1518 in patients with myelofibrosis. EHA Annu Meet Abstr 95:1444","journal-title":"EHA Annu Meet Abstr"},{"key":"2697_CR102","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1182\/blood-2013-02-484832","volume":"125","author":"RS Komrokji","year":"2015","unstructured":"Komrokji RS, Seymour JF, Roberts AW, et al. (2015) Results of a phase 2 study of pacritinib (SB1518), a JAK2\/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood 125:2649\u20132655. doi: 10.1182\/blood-2013-02-484832","journal-title":"Blood"},{"key":"2697_CR103","first-page":"58","volume":"126","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Mesa RA, Cervantes F, et al. (2015) Analysis of outcomes by patient subgroups in patients with myelofibrosis treated with pacritinib vs best available therapy (BAT) in the phase III Persist-1 trial. ASH Annu Meet Abstr 126:58","journal-title":"ASH Annu Meet Abstr"},{"key":"2697_CR104","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/2040620715586527","volume":"6","author":"AB Duenas-Perez","year":"2015","unstructured":"Duenas-Perez AB, Mead AJ (2015) Clinical potential of pacritinib in the treatment of myelofibrosis. Ther Adv Hematol 6:186\u2013201. doi: 10.1177\/2040620715586527","journal-title":"Ther Adv Hematol"},{"key":"2697_CR105","unstructured":"PR Newswire (2016) CTI BioPharma provides update on clinical hold of investigational agent pacritinib and new drug application in U.S. http:\/\/www.prnewswire.com\/news-releases\/cti-biopharma-provides-update-on-clinical-hold-of-investigational-agent-pacritinib-and-new-drug-application-in-us-300217839.html . Accessed 12 February 2016"},{"key":"2697_CR106","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.1182\/blood-2009-05-223727","volume":"115","author":"JW Tyner","year":"2010","unstructured":"Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E, Deininger MW (2010) CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 115:5232\u20135240. doi: 10.1182\/blood-2009-05-223727","journal-title":"Blood"},{"key":"2697_CR107","first-page":"2851","volume":"122","author":"J Villeval","year":"2013","unstructured":"Villeval J, Moratal C, Debeurme F, Lacout C, Solary E, Vainchenker W, Burns CJ, Smith G (2013) Effect of the JAK1\/2 inhibitor GS-0387 (momelotinib) on the anemia associated with a preclinical murine model of human primary myelofibrosis. ASH Annu Meet Abstr 122:2851","journal-title":"ASH Annu Meet Abstr"},{"key":"2697_CR108","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2009.50","volume":"23","author":"A Pardanani","year":"2009","unstructured":"Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A (2009) CYT387, a selective JAK1\/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 23:1441\u20131445. doi: 10.1038\/leu.2009.50","journal-title":"Leukemia"},{"key":"2697_CR109","first-page":"108","volume":"122","author":"A Pardanani","year":"2013","unstructured":"Pardanani A, Gotlib J, Gupta V, et al. (2013) Update on the long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. ASH Annu Meet Abstr 122:108","journal-title":"ASH Annu Meet Abstr"},{"key":"2697_CR110","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","volume":"108","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Barosi G, Mesa RA, et al. (2006) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108:1497\u20131503. doi: 10.1182\/blood-2006-03-009746","journal-title":"Blood"},{"key":"2697_CR111","first-page":"1590","volume":"122","author":"Y Xin","year":"2013","unstructured":"Xin Y, Shao L, Deng W, Niforos D, Kowalski M, Bavisotto LM, Kawashima J, Jun S, Collins H, Ramanathan S (2013) Dose-response analyses of momelotinib (CYT387), a JAK1 and JAK2 inhibitor, from a phase I\/II study (CCL09101) in treatment of myelofibrosis. ASH Annu Meet Abstr 122:1590","journal-title":"ASH Annu Meet Abstr"},{"key":"2697_CR112","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/bjh.13262","volume":"169","author":"RA Abdelrahman","year":"2015","unstructured":"Abdelrahman RA, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Pardanani A, Tefferi A (2015) Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. Br J Haematol 169:77\u201380. doi: 10.1111\/bjh.13262","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2697-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2697-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2697-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2697-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:45:52Z","timestamp":1600649152000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2697-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,21]]},"references-count":112,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["2697"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2697-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,21]]}}}